Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
157M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
38.6M
-
Shares change
-
+2.87M
-
Total reported value, excl. options
-
$548M
-
Value change
-
+$48.8M
-
Put/Call ratio
-
0.53
-
Number of buys
-
68
-
Number of sells
-
-44
-
Price
-
$14.20
Significant Holders of TG THERAPEUTICS, INC. - Common Stock (TGTX) as of Q1 2018
144 filings reported holding TGTX - TG THERAPEUTICS, INC. - Common Stock as of Q1 2018.
TG THERAPEUTICS, INC. - Common Stock (TGTX) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.6M shares
of 157M outstanding shares and own 24.54% of the company stock.
Largest 10 shareholders include venBio Select Advisor LLC (5.23M shares), FMR LLC (4.73M shares), BlackRock Inc. (3.48M shares), STATE STREET CORP (3.12M shares), VANGUARD GROUP INC (2.55M shares), RA CAPITAL MANAGEMENT, LLC (2.47M shares), FRANKLIN RESOURCES INC (2.41M shares), BRIDGER MANAGEMENT, LLC (2.37M shares), UBS ASSET MANAGEMENT AMERICAS INC (951K shares), and COLUMBUS CIRCLE INVESTORS (761K shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.